As of June 2024 Theravance Biopharma has a market cap of $0.41 Billion. This makes Theravance Biopharma the world's 6225th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.41 B | -25.1% |
2023 | $0.55 B | -25.95% |
2022 | $0.75 B | -7.19% |
2021 | $0.81 B | -28.76% |
2020 | $1.14 B | -22.56% |
2019 | $1.47 B | 3.6% |
2018 | $1.42 B | -5.57% |
2017 | $1.50 B | -8.88% |
2016 | $1.65 B | 166.01% |
2015 | $0.62 B | 29.49% |
2014 | $0.48 B |
On Jun 1st, 2024 the market cap of Theravance Biopharma was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Corcept Therapeutics
CORT | $3.14 B | 649.27% | ๐บ๐ธ USA |
Collegium Pharmaceutical
COLL | $1.08 B | 158.62% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | $1.90 B | 355.59% | ๐บ๐ธ USA |
Catalent CTLT | $9.73 B | 2,222.16% | ๐บ๐ธ USA |